The bladder mass medium biopsy (1-3 cm test) is a targeted pathological procedure used to evaluate tissue growths measuring between one and three centimeters located within the urinary bladder.
During cystoscopy, a specialist collects a medium-sized tissue sample from the suspicious lesion. This sample undergoes detailed microscopic examination by a pathologist to determine whether the mass is benign or malignant, and to grade its cellular structure.
Accurately diagnosing a bladder mass of this scale is crucial for staging urothelial carcinoma or other conditions, enabling physicians to formulate precise treatment strategies and surgical interventions.

The bilirubin direct test measures the amount of conjugated (water-soluble) bilirubin in your blood. After raw bilirubin is processed and filtered through the liver, it binds with specific sugars, allowing it to dissolve and pass easily into the bile ducts for excretion.
This specific diagnostic test is vital for determining the precise cause of jaundice and evaluating liver or gallbladder health. Elevated levels of direct bilirubin typically point toward a physical blockage within the biliary tract, gallstones, or intrahepatic cholestasis. By pinpointing conjugated bilirubin levels, physicians can quickly differentiate between various hepatic disorders and targeted pathologies.

The bile acids test is a diagnostic blood or fecal examination that measures the concentration of bile acids circulating in the body. Produced by the liver and stored in the gallbladder, bile acids help digest dietary fats and absorb vital nutrients.
This test is primarily used to evaluate liver function, diagnose chronic liver diseases, detect intrahepatic cholestasis of pregnancy, and assess gastrointestinal malabsorption issues. Abnormally elevated or lowered levels can indicate impaired hepatic clearance, biliary tract blockages, or disrupted enterohepatic circulation, providing critical insights for targeted medical intervention.

A **Basic Arthritis Profile for Male** is a targeted blood panel designed to evaluate systemic inflammation and identify markers associated with various arthritic conditions. This profile typically includes tests such as Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) to detect generalized inflammatory responses, along with Rheumatoid Factor (RF) and sometimes Anti-CCP to screen for autoimmune joint diseases. Additionally, Uric Acid levels are frequently measured to assess for gout, a condition notably prevalent in men. By analyzing these specific biomarkers, healthcare providers can differentiate between inflammatory and non-inflammatory joint pain, facilitating an accurate diagnosis and timely intervention to preserve long-term joint health.

An **Arthritis Profile B test** is an expanded, multi-parameter diagnostic panel designed to comprehensively evaluate complex joint disorders and autoimmune inflammatory conditions. In addition to core markers like **Rheumatoid Factor (RF)**, **C-Reactive Protein (CRP)**, and **Erythrocyte Sedimentation Rate (ESR)**, Profile B typically incorporates specialized biomarkers such as **Anti-CCP**, **Anti-Nuclear Antibodies (ANA)**, **ASO Titre**, **HLA-B27**, **Complement 3 (C3)**, and **Vitamin D levels**.
Clinicians order this extensive profile for patients presenting with persistent joint pain, morning stiffness, or suspected systemic autoimmune diseases like ankylosing spondylitis or lupus. It provides deep diagnostic insight to differentiate overlapping arthritic conditions and guide targeted therapy.

The **Activated Partial Thromboplastin Time (APTT)** test is a essential coagulation screening assay that evaluates the integrity of the intrinsic and common pathways of the blood clotting cascade. It measures the time, in seconds, required for a fibrin clot to form in plasma after specific activating reagents and calcium are added. Clinically, the APTT is primary used to monitor unfractionated heparin anticoagulant therapy and to investigate unexplained bleeding or bruising. Prolonged APTT values can indicate deficiency or dysfunction of clotting factors—such as Factor VIII in Hemophilia A or Factor IX in Hemophilia B—or the presence of circulating inhibitors like lupus anticoagulant.

**Apolipoprotein A1 (ApoA1)** is the primary structural protein component of High-Density Lipoprotein (HDL), commonly known as "good cholesterol." Produced mainly in the liver and intestine, ApoA1 plays a critical role in **reverse cholesterol transport**—a protective process where excess cholesterol is collected from peripheral tissues and artery walls, then transported back to the liver for excretion. Additionally, ApoA1 acts as a cofactor for lecithin-cholesterol acyltransferase (LCAT), an enzyme essential for converting free cholesterol into esterified forms for transport. Higher circulating levels of ApoA1 are strongly associated with reduced cardiovascular risk, anti-inflammatory defense, and improved vascular endothelial function.

An **Activated Protein C Resistance (APCR)** test is a specialized blood investigation used to evaluate a person’s risk for developing abnormal blood clots. Activated Protein C (APC) is a natural anticoagulant protein in the body that inactivates specific clotting factors to prevent excessive coagulation.
In APCR, the blood’s response to APC is diminished, leading to a higher tendency to form blood clots—a condition known as thrombophilia. Most commonly caused by the Factor V Leiden genetic mutation, this test measures how long it takes for plasma to clot after adding APC. Identifying APCR helps clinicians assess venous thromboembolism risk and tailor preventive therapies effectively.

The **Anti-Mullerian Hormone (AMH) test** is a blood test that measures the levels of AMH, a hormone produced by the small, growing follicles in a woman's ovaries. Because the amount of AMH in the blood directly corresponds to the number of remaining eggs, the test is widely used to assess a woman’s ovarian reserve (egg count).

This diagnostic tool is valuable in fertility planning, helping to predict responses to IVF treatments and evaluate conditions like Polycystic Ovary Syndrome (PCOS). Additionally, it can help estimate the onset of menopause or investigate early ovarian insufficiency.

**Anti-Infliximab Antibodies (ATIs)** are immune proteins produced by the body that mistakenly target and neutralize infliximab, a biologic medication used to treat autoimmune conditions like Crohn's disease and rheumatoid arthritis.

When a patient develops ATIs, the antibodies bind to the drug, clearing it from the bloodstream much faster than normal. This primary response leads to a significant drop in drug efficacy, often causing a return of disease symptoms (loss of response). Additionally, the formation of these immune complexes increases the risk of acute infusion reactions, such as fever, chills, or rashes, during treatment.
An Anti-Infliximab Antibodies (ATI) diagnostic test measures the level of these neutralizing antibodies in a patient's blood, typically alongside infliximab drug levels. This dual assessment, known as therapeutic drug monitoring (TDM), is crucial when a patient is losing response to treatment.

An **Anemia Profile - B** is an advanced diagnostic panel designed to investigate complex or persistent cases of anemia that go beyond basic iron deficiency. This profile evaluates critical macrocytic and underlying physiological factors influencing red blood cell production.

It typically includes quantitative measurements of Vitamin B12 and Folic Acid (Folate), which are essential for proper DNA synthesis and erythrocyte maturation. Additionally, it may assess vital iron markers like ferritin, serum iron, and total iron-binding capacity. This comprehensive approach helps clinicians accurately differentiate between megaloblastic anemias, pernicious anemia, and anemias of chronic disease, guiding effective, targeted therapies.